Syndax Pharmaceuticals Inc.
SNDX | NASDAQ
$18.26
+$0.19 (+1.05%)
Sep 22, 2026, 9:38 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 172.35M | 23.68M | n/a | n/a | 139.71M | 1.52M |
Cost of Revenue | 6.97M | 826K | n/a | n/a | n/a | n/a |
Gross Profit | 165.38M | 22.85M | n/a | n/a | 139.71M | 1.52M |
Operating Income | -273.08M | -339.67M | -229.95M | -151.76M | 26.22M | -71.42M |
Interest Income | 22.73M | 26.09M | 21.16M | 5.87M | 403K | 841K |
Pretax Income | -285.42M | -318.76M | -209.36M | -149.34M | 24.93M | -73.16M |
Net Income | -285.42M | -318.76M | -209.36M | -149.34M | 24.93M | -73.07M |
Selling & General & Admin | 179.68M | 120.88M | 66.92M | 33.26M | 25.24M | 22.51M |
Research & Development | 258.78M | 241.65M | 163.03M | 118.5M | 88.25M | 50.44M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 438.47M | 362.53M | 229.95M | 151.76M | 113.49M | 72.94M |
Interest Expense | 33.79M | 4.93M | 208K | 3.14M | 1.9M | 2.36M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 445.44M | 363.35M | 229.95M | 151.76M | 113.49M | 72.94M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 86.63M | 85.62M | 70.37M | 60.76M | 52.06M | 41.31M |
Shares Outstanding (Diluted) | 86.63M | 85.62M | 70.37M | 60.76M | 52.06M | 41.31M |
EPS (Basic) | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 |
EPS (Diluted) | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 |
EBITDA | -251.63M | -313.82M | -209.14M | -146.17M | 26.87M | -70.29M |
EBIT | -251.64M | -313.83M | -209.15M | -146.2M | 26.83M | -70.8M |
Depreciation & Amortization | 6K | 8K | 12K | 33K | 43K | 515K |
Add to Watchlist
Select watchlists to add or remove SNDX